TABLE 1.
The baseline characteristics of all patients
| Characteristics | All patients (n = 161) |
|---|---|
| Age (≥60 years) | 36 (22.36) |
| Male | 144 (89.44) |
| BMI | 22.71 ± 3.46 |
| Drinking history | 58 (36.02) |
| Smoking history | 70 (43.48) |
| ECOG‐PS | |
| 0 | 81 (50.31) |
| 1 | 67 (41.61) |
| 2 | 13 (8.08) |
| The lines of therapy | |
| First‐line therapy | 130 (80.75) |
| Second‐line therapy | 31 (19.25) |
| Child–Pugh Class | |
| A | 128 (79.50) |
| B | 33 (20.50) |
| Ascites | 33 (20.50) |
| PVTT | 88 (54.66) |
| Comorbidity | |
| Hypertension | 32 (19.88) |
| Diabetes | 18 (11.18) |
| Hepatitis B | 145 (90.06) |
| Liver cirrhosis | 120 (74.53) |
| Splenomegaly | 28 (17.39) |
| Previous treatment | |
| Surgery | 38 (23.60) |
| Ablation | 35 (21.74) |
| TACE | 91 (56.52) |
| HAIC | 23 (14.29) |
| Laboratory finding | |
| WBC count (×109/L) | 5.80 (4.58–7.53) |
| Lymphocyte count (≥1.1 × 109/L) | 110 (68.32) |
| Neutrophil count (×109/L) | 3.57 (2.74–4.99) |
| AST (U/L) | 44 (30–66) |
| ALT (U/L) | 34 (22–51) |
| Total bilirubin (≥34 μmol/L) | 9 (5.59) |
| ALB (≥35 g/L) | 110 (68.32) |
| PT (s) | 11.90 (11.00–12.70) |
| AFP (≥200 ng/ml) | 98 (60.87) |
| Platelet count (<100 × 109/L) | 23 (14.29) |
Note: Normally distributed continuous variable data are presented as mean ± standard deviation. Non‐normally distributed continuous variable data are presented as median (interquartile ranges). Classified variable data are presented as n (%).
Abbreviations: AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ECOG‐PS, Eastern Cooperative Oncology Group performance status; HAIC, hepatic arterial infusion chemotherapy; PT, prothrombin time; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization; WBC, white blood cell.